Evaluation of a species-specific C-reactive protein assay for the dog on the ABX Pentra 400 clinical chemistry analyzer

Hindenberg, Sarah; Klenner-Gastreich, Stefanie; Kneier, Nicole; Zielinsky, Sabine; Gommeren, Kris; Bauer, Natali; Moritz, Andreas

doi:10.1186/s12917-017-1065-9

Cited by 19 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemolysis, lipemia, and hyperbilirubinemia can influence CRP measurements but we did not find a significant effect of these factors on CRP measurements. According to previously reported data, interference would indeed only be expected at very high concentrations of hemoglobin (5 g/L), intralipid (10 g/L), and bilirubin (800 mg/L).…”

Section: Discussionmentioning

confidence: 99%

“…Serum CRP concentration was measured according to the manufacturer's instructions, using a previously validated dog‐specific immunoturbidimetric CRP assay on a fully automated clinical chemistry analyzer . In summary, the main reagent is a polyclonal chicken anti‐canine CRP antibody, which generates increased sample turbidity upon reaction with canine CRP.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory cytokine and C‐reactive protein concentrations in dogs with systemic inflammatory response syndrome

Gommeren

Desmas

García

et al. 2017

J Vet Emergen Crit Care

Self Cite

View full text Add to dashboard Cite

Objective -To evaluate C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-␣) kinetics in dogs with a systemic inflammatory response syndrome (SIRS) presented to an emergency service. We hypothesized serum CRP concentrations would increase and vary during hospitalization, and would correlate with plasma IL-6 and TNF-␣ concentrations, vary in magnitude according to the underlying disease, and predict survival. Design -Prospective, observational, clinical study. Setting -University emergency department. Animals -Sixty-nine dogs with SIRS weighing over 5 kg who could tolerate the blood sampling. Interventions -Serum and plasma were collected (and stored at -80°C) at presentation (T0), after 6 (T6), 12 (T12), 24 (T24), and 72 (T72) hours, and at a follow-up visit at least 1 month after discharge (T1m). Underlying diseases were categorized as infection (I), neoplasia (N), trauma (T), gastric-dilation and volvulus (GDV), other gastrointestinal (GI), renal (R), and miscellaneous (M) disease. Measurements and Main Results -Serum CRP concentration was measured using a canine-specific immunoturbidimetric assay. Biologically active plasma IL-6 and TNF-␣ concentrations were assessed using bioassays. Forty-four dogs survived, 8 died, and 17 were euthanized. Nineteen dogs had follow-up visits. At T0, serum CRP concentration was above the reference interval in 73.1% (49/67), and was within the reference interval (0-141.9 nmol/L) throughout hospitalization in only 6% (4/67). Serum CRP concentrations were significantly higher (P < 0.0001) at T0 (882.9 ± 1082.9 nmol/L) and at all time points during hospitalization (P < 0.0001) compared to T1m, with highest concentrations observed at T24 (906. 7 ± 859.0 nmol/L). At T1m, serum CRP concentrations were within the reference interval (22.9 ± 42.9 nmol/L) in 95% (18/19) of dogs. Logarithmic concentrations of serum CRP and plasma IL-6 were significantly correlated (P < 0.001, r = 0.479). None of the measured cytokines were associated with disease category or outcome. Conclusions -Serum CRP concentration is increased in dogs with SIRS, and decreases during treatment and hospitalization. Serum CRP, plasma IL-6, and plasma TNF-␣ concentrations cannot predict outcome in dogs with SIRS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Inflammatory cytokine and C‐reactive protein concentrations in dogs with systemic inflammatory response syndrome

Gommeren

Desmas

García

et al. 2017

J Vet Emergen Crit Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…Analyses were performed on surplus lithium heparin plasma submitted for CRP analysis to the Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig-University Giessen, Germany. Samples were analyzed immediately (< 1 h after blood collection) with the Gentian Canine CRP Immunoassay (Gentian AS, Moss, Norway), which served as the reference assay, on the ABX Pentra 400 clinical chemistry analyzer (ABX Horiba, Montpellier, France) as described before [ 29 ]. The initially performed CRP analysis as part of routine diagnostics was used to assign the sample to one of the three concentration ranges: CRP 10–50 mg/l (low); 50–100 mg/l (medium), and 100–200 mg/l (high).…”

Section: Methodsmentioning

confidence: 99%

“…Thus, it was the aim of our study to evaluate the ease of use and the test performance including linearity and lower limit of quantification (LoQ), precision and total observed error (TE obs ) as well as interferences with bilirubin, hemoglobin and lipid of the canine species-specific in-house CRP assay run on the Point Reader™ V. In a method comparison study, the assay was compared with a canine CRP test which has been validated before [ 20 , 29 ] run on two automated analyzers serving as reference methods. Furthermore, the reference range was evaluated.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a novel quantitative canine species-specific point-of-care assay for C-reactive protein

Hindenberg¹,

Keßler²,

Zielinsky³

et al. 2018

BMC Vet Res

Self Cite

View full text Add to dashboard Cite

BackgroundSpecies-specific point-of-care tests (POCT) permit a rapid analysis of canine C-reactive protein (CRP), enabling veterinarians to include CRP in clinical decisions. Aim of the study was to evaluate a novel POCT for canine CRP (Point Strip™ Canine CRP Assay) run on a small in-house-analyzer (Point Reader™ V) using lithium heparin plasma and to compare assay performance to an already established canine CRP assay (Gentian Canine CRP Immunoassay) run on two different bench top analyzers serving as reference methods (ABX Pentra 400, AU 5800).Linearity was assessed by stepwise dilution of plasma samples with high CRP concentrations. Limit of quantification (LoQ) was determined by repeated measurements of samples with low CRP concentrations. Coefficient of variation (CV) at low (10–50 mg/l), moderate (50–100 mg/l), and high (100–200 mg/l) CRP concentrations was investigated as well as possible interferences. Method comparison study was performed using 45 samples of healthy and diseased dogs. Quality criteria were fulfilled if the total observed error (TEobs = 2CV% + bias%) was below the minimal total allowable error of 44.4% (TE min). Additionally, a reference range (n = 60 healthy dogs) was established.ResultsLinearity was present at CRP concentrations of 10–132 mg/l (≙ 361 mg/l CRP with reference method) with a LoQ set at 10 mg/l. At moderate to high CRP concentrations, intra- and inter-assay CVs were ≤ 8% and ≤ 11% respectively, while CVs ≤ 22% and ≤ 28% were present at low concentrations. No interferences were observed at concentrations of 4 g/l hemoglobin, 800 mg/l bilirubin and 8 g/l triglycerides. Method comparison study demonstrated an excellent correlation with both reference methods (r = 0.98 for ABX Pentra 400; 0.99 for AU 5800), though revealing a proportional bias of 19.7% (ABX Pentra 400) and 10.7% (AU 5800) respectively. TEobs was 26.7–31.9% and 16.7–21.9% and thus < TEmin. Healthy dogs presented with CRP values ≤11.9 mg/l.ConclusionsThe POCT precisely detects canine CRP at clinically relevant moderate and high CRP concentrations. The assay correlates well with both reference methods. Due to the bias, however, follow-up examinations should be performed with the same assay and analyzer.

show abstract

“…Quantification of canine CRP in serum can be done using several assay formats,81, 82, 83, 84, 85, 86, 87, 88 all of which have a reference interval of approximately 0–8 mg/L. A high‐sensitivity CRP (hs‐CRP) assay with improved sensitivity for lower serum CRP concentrations89, 90 currently is not routinely available in veterinary medicine 91…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Evaluation of a species-specific C-reactive protein assay for the dog on the ABX Pentra 400 clinical chemistry analyzer

Cited by 19 publications

References 38 publications

Inflammatory cytokine and C‐reactive protein concentrations in dogs with systemic inflammatory response syndrome

Inflammatory cytokine and C‐reactive protein concentrations in dogs with systemic inflammatory response syndrome

Evaluation of a novel quantitative canine species-specific point-of-care assay for C-reactive protein

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Contact Info

Product

Resources

About